Trial intelligence / Profile preview

Infliximab Extension in Korean RA Patients

NCT00732875Phase 3Completed

Sponsor
Merck & Co.
Start
Aug 2006
Primary completion
May 2008
Modality
Monoclonal Antibodies
01

Overview

A Phase 3 trial of infliximab in rheumatoid arthritis (RA), sponsored by Merck & Co.. Started Aug 2006; status: completed.

02

Drugs

infliximab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on NCT00732875.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00732875.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call